MS and Demyelinating Disorders

Here's what is coming soon to NeurologyLive®.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Alzheimer disease and dementia.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 1, 2022.

In a sensitivity analysis that excluded women with evidence of possible demyelinating events before MS diagnosis, the associations between pregnancy-related ICD-10 code recording and disease risk were even more pronounced.

Klaus Schmierer, MB BS, PhD, FRCP, concludes with advice for community physicians and neurologists who are managing patients with MS and COVID-19 or vaccinations.

Dr Schmierer discusses the general guideline vaccination recommendations for patients with MS.

Here's what is coming soon to NeurologyLive®.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is headache and migraine.

Neurology News Network for the week ending March 26, 2022. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 25, 2022.

Mind Moments™, a podcast from NeurologyLive®, brings you an exclusive interview with Friedmann Paul, MD. [LISTEN TIME: 27 minutes]

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive® team.

The overall attributable fraction of multiple sclerosis due was 13.1%, in comparison with just 0.6% of ex-smokers, indicating the beneficial effects of smoking cessation.

Data from the ProTEct-MS trial (NCT04480307) suggest that temelimab is safe and well-tolerated in patients with relapsing MS also treated with rituximab, and data were consistent with prior findings. More analysis will be necessary to define an optimal dose.

Here's what is coming soon to NeurologyLive®.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is optic neuritis and neuromyelitis optica spectrum disorder (NMOSD).

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 18, 2022.

An expert delves into the different types of immune responses a patient with MS can have to COVID-19 vaccines if they are also on DMTs.

Dr Schmierer explains how the SARS-CoV-2 infection and COVID-19 pandemic have impacted treating patients with MS with DMTs.

Looking to the future of multiple sclerosis care, the panel of thought leaders pose important questions that remain to be answered in the research and treatment of multiple sclerosis.

Expert panelists review the viability of new treatments in development for multiple sclerosis.

Alberto Ascherio, MD, DrPH, addresses the range of latency periods for Epstein-Barr virus and the impact on onset multiple sclerosis.

Alberto Ascherio, MD, DrPH; Anne Cross, MD; and Michael Racke, MD, discuss implications for patient communication and other advances from bench to bedside.

The expert panelists comment on intervention efforts underway to address multiple sclerosis prevention and treatment.

A panel of experts probe the variations in immune response to Epstein-Barr virus in patients with multiple sclerosis.

Alberto Ascherio, MD, DrPH, highlights key risk factors leading to increased prevalence of multiple sclerosis.

Anne Cross, MD, and Michael Racke, MD, discuss how the immune system is primed in multiple sclerosis.

Avindra Nath, MD, explains the importance of understanding virology when treating autoimmune diseases.

Alberto Ascherio, MD, DrPH, recaps key findings and learning from a recently published study that he coauthored demonstrating a causal relationship between MS and Epstein-Barr virus.

The staff neurologist and medical director of the Barlo Multiple Sclerosis Program at St Michaels Hospital discussed how investigational BTK inhibitors will be used among an ever-growing MS treatment toolbox. [WATCH TIME: 3 minutes]